Skip to main content
. 2023 May 9;17(10):1631–1638. doi: 10.1093/ecco-jcc/jjad079

Table 4.

Demography and characteristics of the study cohorts including male IBD patients following colectomy and a matched referent cohort from the general population.

IBD subcohorts
Characteristics Matched cohort [n = 19 502] IBD-cohort [n = 3771] UC [n = ,850] CD [n = 321] IBD-U [n = 1600]
Age at diagnosis, years, mean [SD] 26.34 [8.55] 26.36 [8.58] 27.64 [8.42] 25.16 [8.32] 25.11 [8.60]
Age at colectomy, years, mean [SD] 30.40 [8.12] 30.41 [8.13] 31.20 [7.99] 29.18 [8.49] 29.73 [8.14]
Age at reconstruction, years, mean [SD] 35.62 [12.27] 35.62 [12.28] 35.77 [11.86] 36.91 [14.73] 35.19 [12.20]
Follow-up time, years, mean [SD] 11.63 [7.12] 11.34 [7.21] 10.37 [6.76] 13.90 [8.09] 11.95 [7.33]
Time to colectomy, years, mean [SD] 4.06 [5.37] 4.05 [5.38] 3.57 [5.13] 4.02 [5.74] 4.61 [5.53]
Time to reconstruction, years, mean [SD] 5.22 [9.90] 5.21 [9.90] 4.56 [9.15] 7.73 [13.60] 5.46 [9.77]
Age at first child, years, mean [SD] 28.96 [5.44] 29.29 [5.41] 29.41 [5.32] 28.11 [5.28] 29.39 [5.52]
Parity at diagnosis, mean [SD] 0.63 [1.03] 0.57 [0.97] 0.64 [1.01] 0.50 [0.91] 0.51 [0.93]
Parity at colectomy, mean [SD] 0.88 [1.15] 0.78 [1.07] 0.83 [1.10] 0.73 [1.04] 0.74 [1.04]
Achieved parity at end of follow-up, mean [SD] 1.57 [1.31] 1.38 [1.25] 1.37 [1.26] 1.38 [1.28] 1.39 [1.23]
No child at diagnosis, no. [%] 12 993[66.6%] 2594 [68.8%] 1211 [65.5%] 229 [71.3%] 1154 [72.1%]
No child at colectomy, no. [%] 10 770 [55.2%] 2210 [58.6%] 1049 [56.7%] 191 [59.5%] 970 [60.6%]
No child at end of follow-up, no. [proportion] 5,799 [29.7%] 1325 [35.1%] 660 [35.7%] 114 [35.5%] 551 [34.4%]
Year of colectomy, no. [%] 1950–1979 2563 [13.1%] 493 [13.1%] 211 [11.4%] 87 [27.1%] 195 [12.2%]
1980–1989 4330 [22.2%] 835 [22.1%] 382 [20.6%] 115 [35.8%] 338 [21.1%]
1990–1999 5387 [27.6%] 1047 [27.8%] 529 [28.6%] 67 [20.9%] 451 [28.2%]
2000–2009 4853 [24.9%] 940 [24.9%] 488 [26.4%] 30 [9.3%] 422 [26.4%]
2010–2014 2369 [12.1%] 456 [12.1%] 240 [13.0%] 22 [6.9%] 194 [12.1%]

Inflammatory bowel disease [IBD], ulcerative colitis [UC], Crohn’s disease [CD], IBD unclassified [IBD-U].